As of 30 Sep 2025, 9 institutional investors reported holding $28,696,440 in principal (par value) of ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | $28,696,440 | $40,994,280 | -$5,776,275 | 99.8% | 9 |
| 2025 Q2 | $21,445,940 | $40,691,968 | +$258,846 | 98.57% | 11 |
| 2025 Q1 | $17,805,940 | $37,176,006 | +$4,761,261 | 98.3% | 9 |
| 2024 Q4 | $33,246,000 | $32,179,247 | -$171,475,182 | 96.97% | 6 |
| 2024 Q3 | $206,228,879 | $255,900,035 | -$4,680,086 | 94.87% | 16 |
| 2024 Q2 | $152,469,254 | $187,829,878 | +$195,239 | 92.32% | 18 |
| 2024 Q1 | $208,792,404 | $218,541,156 | -$14,900,797,445 | 83.07% | 18 |
| 2023 Q4 | $251,483,000 | $155,407,577 | +$10,559,097 | 58.38% | 19 |
| 2023 Q3 | $233,149,851 | $140,405,628 | -$3,874,535 | 52.0% | 18 |
| 2023 Q2 | $229,653,351 | $129,965,639 | -$6,731,939 | 49.73% | 19 |
| 2023 Q1 | $254,048,851 | $113,326,121 | -$608,415 | 40.11% | 21 |
| 2022 Q4 | $239,283,608 | $139,754,556 | +$3,066,323 | 54.56% | 22 |
| 2022 Q3 | $244,886,087 | $152,197,175 | -$42,810 | 55.78% | 21 |
| 2022 Q2 | $244,986,087 | $147,153,000 | +$772,824 | 54.43% | 21 |
| 2022 Q1 | $242,165,014 | $138,366,000 | +$5,204,812 | 51.57% | 21 |
| 2021 Q4 | $199,921,591 | $115,537,000 | +$115,537,632 | 52.75% | 17 |